The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000827336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
27/05/2026
Date registered
Help: Date registered
9/07/2026
Date last updated
Help: Date last updated
10/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A 4-week, first in human study assessing the safety and tolerability of different doses of oral insulin (EA-Ins-IQ-100) in healthy volunteers
Scientific title
A Phase Ia, randomised, double blind, placebo-controlled study to assess the safety and tolerability of single ascending doses of the oral insulin formulation EA- Ins-IQ-100 in healthy volunteers.
Additional trial identifiers [1] 317397 0
EA-Ins-IQ-100-01
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Type 1 Diabetes 342061 0
Condition category
Condition code
Metabolic and Endocrine 338160 338160 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
12 participants will be randomly assigned to a unique placebo-controlled ascending dosing schedule in this study. Dosing will consist of 4 dosing days spaced apart by at least 1 week. The four dosing days will involve 4 doses of EA-Ins-IQ-100 in ascending strengths as follows:
Dosing day 1: 2.25mg (equiv. to 62.5IU in 1 capsule),
Dosing Day 2: 4.5mg (equiv. to 125IU in 2 capsules),
Dosing Day 3: 6.75mg (equiv, to 187.5 IU in 3 capsules)
Dosing Day 4: 9mg (equiv. to 250IU in 4 capsules).
Participants will either receive placebo or EA-Ins-IQ-100 at each dosing day. 2 Sentinel participants will receive 2 doses of active and 2 placebo doses in the four dosing days. The rest of the cohort will be assigned 3 active doses and 1 placebo dose for their four dosing days.
Intervention code [1] 334192 0
Treatment: Drugs
Description of the comparator or control
Matched placebo capsules, identical to the EA-Ins-IQ-100 oral insulin capsules. Placebo capsules are filled with an excipient powder of microcrystalline cellulose.
Control group
Placebo

Outcomes
Primary outcome [1] 345545 0
Adverse Events -The incidence, severity, frequency/persistence and seriousness of Adverse Events at each dose compared to placebo.
Timepoint [1] 345545 0
At Screening; Admission; Day 1 pre-dose, Day 1 at the time of dosing, Day 1 post-dosing at the 15-min, 30 min, 45 min, 1 hour, 1 hour 15 min, 1 hour 30 min, 1 hour 45 min, 2 hour, 2 hour 30 min, 3 hour, 4 hour, 8 hour; Day 27 post-dose.
Primary outcome [2] 345989 0
The safety and tolerability of single ascending doses of Ins-IQ using the incidence, severity, frequency/persistence and seriousness of symptomatic hypoglycaemic episodes for each dose, compared to placebo. This will be assessed as a composite outcome.
Timepoint [2] 345989 0
At Screening; Admission; Day 1 pre-dose, Day 1 at the time of dosing, Day 1 post-dosing at the 15-min, 30 min, 45 min, 1 hour, 1 hour 15 min, 1 hour 30 min, 1 hour 45 min, 2 hour, 2 hour 30 min, 3 hour, 4 hour, 8 hour; Day 27 post-dose.
Primary outcome [3] 345990 0
To assess the safety and tolerability of single ascending doses of Ins-IQ using the incidence of Adverse Events of Special Interests (AESIs) for each dose compared to placebo. This will be assessed as a composite outcome.
Timepoint [3] 345990 0
At Screening; Admission; Day 1 pre-dose, Day 1 at the time of dosing, Day 1 post-dosing at the 15-min, 30 min, 45 min, 1 hour, 1 hour 15 min, 1 hour 30 min, 1 hour 45 min, 2 hour, 2 hour 30 min, 3 hour, 4 hour, 8 hour timepoints; Day 27 post-dose.
Secondary outcome [1] 462114 0
Blood Glucose levels
Timepoint [1] 462114 0
0 hours, .25 hours, .5hours, .75 hours, 1 hour, 1.25 hours, 1.5 hours, 1.75 hours, 2 hours, 2.5 hours, 3hours, 4 hours post dose on dosing days 1, 2, 3, 4.

Eligibility
Key inclusion criteria
Healthy volunteers with no significant underlying conditions, as evidenced by ECG, blood sampling and medical history review.
willing and able to understand and sign a consent form.
Body weight between 50-100Kg and BMI between 18 and 32 kg/m2
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
History or presence of clinically significant gastrointestinal pathology or symptoms, liver or kidney disease or any condition that might interfere with the absorption, distribution, metabolism or excretion of the drug in the opinion of the principal investigator or delegate.
Positive pregnancy test or currently breastfeeding
eGFR < 60mL/min/1.73m2
Evidence of impaired hepatic function, as evidenced by ALT or AST greater than or equal to 1,5 x ULN; OR total bilirubin >1.5 x ULN
Current or chronic history of liver disease.
History of severe allergic reaction, or anaphylaxis to drugs or food.
Has an active, acute or chronic infection
Positive urine drug screen and/ or alcohol breath test during screening or on day -1.
Clinically significant changes on ECG
Has a QTcF interval greater than 450 msec for males, greater than 470 for females, has a complete left bundle branch block, or has a history or current evidence of additional risk factors for torsades de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome) at screening
Any other conditions for which, in the opinion of the principal investigator or delegate, participation would not be in the best interested of the participant, or that could prevent, limit, or confound the protocol-specified assessment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation controlled by unblinded pharmacist from randomisation schedule. The pharmacist, located at a separate location, will dispense the required product (Ins-IQ or placebo) from the randomisation schedule into a receptacle that does not identify whether the contents are active or placebo. This receptacle is delivered to the clinical trial unit, labelled with the participant's unique identifier.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Assignment is based on the randomisation master list. Each participant will be assigned a unique randomisation number. That number will be on the randomisation list, containing the unique combination of placebo and Ins-IQ doses across the 4 dosing days.
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29549 0
CMAX Clinical Research Pty Ltd - Adelaide
Recruitment postcode(s) [1] 45871 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 321969 0
Commercial sector/Industry
Name [1] 321969 0
Endo Axiom Pty Ltd
Country [1] 321969 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Endo Axiom Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324847 0
None
Name [1] 324847 0
Address [1] 324847 0
Country [1] 324847 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320506 0
Bellberry Human Research Ethics Committee C
Ethics committee address [1] 320506 0
Ethics committee country [1] 320506 0
Australia
Date submitted for ethics approval [1] 320506 0
14/01/2026
Approval date [1] 320506 0
24/03/2026
Ethics approval number [1] 320506 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150694 0
Prof Sepehr Shakib
Address 150694 0
CMAX Clinical Research Pty Ltd. 21/24 North Terrace, Adelaide SA 5000
Country 150694 0
Australia
Phone 150694 0
+61 411100278
Fax 150694 0
Email 150694 0
Contact person for public queries
Name 150695 0
Samantha Guthrie
Address 150695 0
Endo Axiom Pty Ltd, 1102/2 Elizabeth Plaza, North Sydney, NSW 2060.
Country 150695 0
Australia
Phone 150695 0
+610447410422
Fax 150695 0
Email 150695 0
Contact person for scientific queries
Name 150696 0
Prof. Nick Hunt
Address 150696 0
Endo Axiom Pty Ltd. 1102/2 Elizabeth Plaza, North Sydney NSW 2060.
Country 150696 0
Australia
Phone 150696 0
+61 425569108
Fax 150696 0
Email 150696 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.